hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06316596 id: 2011-KAEK-25 2023/09-16 briefTitle: Brain Oxygenation in Newborns Due to Neuroaksial Methods acronym: oxygenation overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-05-01 date: 2024-05-01 date: 2024-03-18 date: 2024-03-18 name: Bursa Yüksek İhtisas Education and Research Hospital class: OTHER_GOV briefSummary: Epidural and spinal anesthesia techniques are frequently used all over the world in elective cesarean section operations. To evaluate the effects of epidural and spinal anesthesia techniques applied in cesarean section surgery on neonatal cerebral oxygenation using Near Infrared Spectroscopy (NIRS). conditions: Cesarean Section conditions: Pregnancy Related conditions: Cerebral Hypoxia conditions: Anesthesia, Regional conditions: Oxygen Saturation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The research is a prospective controlled,randomized,double-blind study primaryPurpose: PREVENTION masking: SINGLE maskingDescription: The research is a prospective, randomized, single-blind, parallel group study. In the study, the Quincke needle will be used for spinal anesthesia and the Tuoghy needle will be used for epidural anesthesia. Oxygenation will be evaluated with the help of NIRS probe in the post-cesarean newborns of pregnant women who will undergo elective cesarean section.
Vitals will be monitored throughout the case with electrocardiography (ECG), non-invasive blood pressure monitoring and spO2. The amount of vasopressor agent and hydration required by the mother throughout the case will be recorded. While one anesthesiologist will monitor the anesthesia method and maternal vitals, the other anesthetist will monitor the NIRS monitoring attached to the newborn. whoMasked: PARTICIPANT count: 80 type: ESTIMATED name: Spinal Anesthesia name: Epidural Anesthesia measure: Near İnfrared Spectroscopi measure: Maternal mean arterial pressure measure: Newborn vitalty measure: Newborn vitalty sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
nctId: NCT06316570 id: HX-A-2023044 id: SF 2024-2-2045 type: OTHER_GRANT domain: Capital health development research project briefTitle: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke acronym: TAPIS overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-01 date: 2026-12-01 date: 2024-03-18 date: 2024-03-19 name: Beijing Tiantan Hospital class: OTHER briefSummary: Early antiplatelet therapy is promising for further improvement of functional prognosis on the basis of intravenous thrombolytic therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of the early dual antiplatelet therapy (within 6 hours of onset ) of ticagrelor with aspirin combined with intravenous thrombolysis in improving good functional outcome (mRS score 0-1) at 90 days inpatients with ischemic stroke. conditions: Ischemic Stroke, Acute studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1380 type: ESTIMATED name: Early Dual Antiplatelet Therapy name: Placebo measure: Excellent functional outcome measure: mRS score of 0-2 points measure: Distribution of mRS score measure: Neurologic improvement measure: Quality of life (EQ-5D scale) measure: Activity of daily living (Barthel index ≥95 points) measure: Recurrent ischemic stroke measure: Symptomatic intracranial hemorrhage (ECASS-III) measure: Symptomatic intracranial hemorrhage (ECASS-III) measure: Parenchymal hematoma type 2 (SIST-MOST) measure: Parenchymal hematoma type 2 (SIST-MOST) measure: Bleeding events (GUSTO) measure: Adverse events measure: Severe adverse events sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06316557 id: HX-A-2022063 briefTitle: High-frequency rTMS on the Cerebellar to Improve Post-stroke Cognitive Impairment acronym: HOPE overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-07-01 date: 2027-04-01 date: 2024-03-18 date: 2024-03-18 name: Beijing Tiantan Hospital class: OTHER briefSummary: The objective of this clinical trial is to investigate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in the cerebellum for individuals with post-stroke cognitive impairment. Participants will undergo rTMS in the cerebellar hemisphere opposite the lesion site, once daily for a total of five days. conditions: Post-stroke Cognitive Impairment conditions: Ischemic Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multicenter Randomized Double-Blind Controlled Study primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 70 type: ESTIMATED name: rTMS group name: control group measure: The efficacy of rTMS in improving cognitive function of post-stroke cognitive impairment measure: The safety of rTMS in improving cognitive function of post-stroke cognitive impairment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06316544 id: CECMed id: 2021ZD0111000 type: OTHER_GRANT domain: National Science and Technology Major Project briefTitle: China Elderly Comorbidity Medical Database acronym: CECMed overallStatus: RECRUITING date: 2023-03-01 date: 2024-11-30 date: 2024-11-30 date: 2024-03-18 date: 2024-03-19 name: Beijing Friendship Hospital class: OTHER name: Chinese Academy of Medical Sciences, Fuwai Hospital name: The First Affiliated Hospital of Zhengzhou University briefSummary: The objective of this observational cohort study is to provide comprehensive evaluation and early warning for elderly patients with chronic diseases. The main question it aims to answer is: How to explore effective evaluation methods for diseases in elderly patients based on the coexistence of multiple diseases and high individual heterogeneity? How to explore the key indicators and influencing factors of adverse events in elderly patients.. Participants will be followed up at 1, 3, 6, 9, and 12 months to obtain adverse event information. conditions: Coronary Artery Disease conditions: Hypertension conditions: Diabetes Mellitus conditions: Osteoporosis conditions: COPD Chronic Obstructive Pulmonary Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 4100 type: ESTIMATED measure: Pneumonia/pulmonary infection measure: respiratory failure measure: pulmonary encephalopathy measure: acute exacerbation of chronic obstructive pulmonary disease measure: unstable angina pectoris measure: acute myocardial infarction measure: acute hemorrhagic stroke measure: acute ischemic stroke measure: acute heart failure/acute exacerbation of chronic heart failure measure: malignant ventricular arrhythmia measure: sudden death measure: falls measure: fractures measure: gastrointestinal bleeding measure: pulmonary embolism measure: deep vein thrombosis measure: diabetes ketoacidosis measure: diabetes hyperosmolar coma measure: rehospitalization measure: admission to ICU sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Beijing Friendship Hospital status: RECRUITING city: Beijing state: Beijing zip: 100050 country: China name: Bingbing Ke, Dr role: CONTACT phone: 15510286857 email: 1017120710@qq.com name: Hongwei Li, Dr role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06316531 id: BL-M07D1-301 briefTitle: A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-05 date: 2026-05 date: 2024-03-18 date: 2024-03-19 name: Sichuan Baili Pharmaceutical Co., Ltd. class: INDUSTRY name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. briefSummary: This study is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable locally advanced or metastatic HER2-positive breast cancer who had failed previous treatment with taxanes and trastuzumab. conditions: HER2-positive Breast Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 268 type: ESTIMATED name: BL-M07D1 name: T-DM1 measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Duration of Response (DOR) measure: Treatment Emergent Adverse Event (TEAE) measure: Anti-drug antibody (ADA) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University city: Guangzhou state: Guangdong country: China name: Erwei Song role: CONTACT name: Erwei Song role: PRINCIPAL_INVESTIGATOR name: Herui Yao role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06316518 id: AIBU-HF-YS-01 briefTitle: The Effect of Mindfulness-Based Web-Based Stress Reduction Program Applied to Primigravidas on Perceived Stress Level in Pregnancy, Birth Self-Efficacy and Prenatal Attachment overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-01 date: 2025-05-01 date: 2024-03-18 date: 2024-03-19 name: Ataturk University class: OTHER briefSummary: The aim of this study is to investigate the effect of a mindfulness-based web-based stress reduction program applied to primigravidas on perceived stress level in pregnancy, birth self-efficacy and prenatal attachment. conditions: Pregnancy Related studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups with a supportive care control groups primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 90 type: ESTIMATED name: mindfulness group measure: Pregnancy Stress Assessment Scale (PSAS) measure: Self-Efficacy Scale for Normal Childbirth measure: Prenatal Attachment Inventory (PAI) sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
nctId: NCT06316505 id: 11/2023-58 briefTitle: Oral Photographs of Patients on Oral Hygiene Motivation overallStatus: COMPLETED date: 2023-12-01 date: 2024-03-01 date: 2024-03-01 date: 2024-03-18 date: 2024-03-21 name: Didem OZKAL EMINOGLU class: OTHER briefSummary: Based on these considerations, this randomized controlled trial aimed to determine the effectiveness of a personalized visual oral health education program in addition to conventional education on oral hygiene by comparing changes in clinical periodontal parameters.
Researchers will compare Intervention group and control groups on oral hygiene by comparing changes in clinical periodontal parameters. conditions: Periodontal Diseases conditions: Motivation conditions: Hygiene studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 56 type: ACTUAL name: Oral hygiene motivation with individual oral photograps measure: Clinical periodontal parameters / plaque index (PI) measure: Clinical periodontal parameters / gingival index (GI) measure: Clinical periodontal parameters / probing pocket depth (PPD). measure: Clinical periodontal parameters / bleeding on probing (BOP) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Atatürk University city: Erzurum zip: 25240_ country: Turkey lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06316492 id: 101919039932 briefTitle: A Study Done by a Demonstrator and Two Professors in Public Health and Community Medicine Department in Faculty of Medicine in Assiut and New Valley University to Assess Knowledge, Attitude ,and Practice of Rural Population in a Remote Governorate ( New Valley ) Towards Hepatitis B and C Viruses acronym: rural_remote overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2024-12-01 date: 2026-06-01 date: 2024-03-18 date: 2024-03-18 name: Assiut University class: OTHER briefSummary: This study is a research aiming to identify knowledge , attitude and practice of population in a village in a remote governorate towards viral hepatitis B and C . It involves home visit interviews with population in this village with the use of questionnaire involving questions asked by the researcher that would be orally answered by the participants to be recorded in papers by the researcher. conditions: Hepatitis B conditions: Hepatitis C studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: CROSS_SECTIONAL count: 450 type: ESTIMATED measure: Assess proportion of adequate knowledge , attitude and practice /behaviour towards viral hepatitis B and C in a rural population in New Valley Governorate measure: Assess proportion of high risk groups of viral hepatitis B and C in these population thus behaviours made them candidates for viral hepatitis B and C infection measure: 2- Proportion of health-seeking behaviour of cases ( confirmation of diagnosis, treatment, and follow up ) and proportion of high risk group seeking for screening sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06316479 id: CI-001-23 briefTitle: Safety and Performance of PTMC Dermal Filler overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2024-12 date: 2025-12 date: 2024-03-18 date: 2024-03-18 name: Aqpha Medical B.V. class: INDUSTRY briefSummary: The goal of this clinical trial is to assess the safety and performance of the PTMC Dermal filler for treating moderate to severe nasolabial folds in adult men and women.
* Each visit will last approximately 60-90 minutes. The visits will be conducted in person. conditions: Moderate to Severe Nasolabial Fold studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: PTMC Dermal Filler measure: Nasolabial fold severity measure: Safety (Adverse events) measure: Nasolabial fold severity measure: Responder rate measure: Overall aesthetic improvement (by the investigator) measure: Overall aesthetic improvement (by the subject) measure: Subject satisfaction measure: Visual Analog Scale (VAS) for pain measure: Treatment satisfaction measure: Ease of use sex: ALL minimumAge: 18 Years maximumAge: 67 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06316466 id: QYFYWZLL28521 briefTitle: Lipoprotein a is an Independent Risk Factor for Overall Survival in Patients With Pancreatic Cancer: a Propensity Score Matching Analysis overallStatus: RECRUITING date: 2023-06-01 date: 2024-01-30 date: 2024-03-30 date: 2024-03-18 date: 2024-03-18 name: jingxue class: OTHER briefSummary: Background: This study aims to assess the prognostic significance of serum lipoprotein (a) \[Lp (a)\] levels on overall survival (OS) and progression free survival (PFS) in individuals diagnosed with pancreatic cancer through the utilization of propensity score matching (PSM).
Methods: A retrospective analysis was conducted on the clinicopathological data of 364 patients diagnosed with pancreatic cancer at the Affiliated Hospital of Qingdao University from January 2019 to December 2022. The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups. We applied PSM analysis to minimize selection bias. The study compared OS and PFS between two groups by Kaplan-Meier method and analyzed differences using the log-rank test. Additionally, univariate and multivariate Cox-regression analyses were performed to identify prognostic factors among patients. conditions: Pancreatic Carcinoma; Lipoprotein a; Overall Survival; Prognosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 360 type: ESTIMATED name: Lp(a) measure: OS measure: PFS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Affiliated Hospital of Qingdao University status: RECRUITING city: Qingdao state: Shandong country: China name: Jinyue Liu role: CONTACT phone: 17854269227 email: liujinyue99@163.com lat: 36.06488 lon: 120.38042 hasResults: False
nctId: NCT06316453 id: PARADISE-PK-09-03-2024 briefTitle: Prospective Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk overallStatus: RECRUITING date: 2024-01-01 date: 2024-10 date: 2024-12 date: 2024-03-18 date: 2024-03-29 name: Advanced Education & Research Center class: OTHER name: University of Karachi name: Pakistan Cardiac Society (Heart House) briefSummary: This study aims to conduct a 10-year follow-up to assess ASCVD risk in Pakistan among individuals aged 30 years and above without a known history of ASCVD. The focus will be on evaluating ASCVD risk over this specific 10-year timeframe. The study will also validate risk assessment scores for identifying high-risk individuals and examine the incidence rate of ASCVD events during long-term follow-up. conditions: Atherosclerotic Cardiovascular Diseases (ASCVD) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 3513 type: ESTIMATED name: Evaluating ASCVD risk over 10 and 30 year and lifetime measure: 10-year ASCVD risk Categorization measure: 30-year ASCVD risk Categorization measure: Lifetime ASCVD risk evaluation measure: Genetic Risk Assessment of ApoB sex: ALL minimumAge: 30 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Advanced Education Institute and Research Center status: RECRUITING city: Karachi state: Sindh zip: 75270 country: Pakistan name: Shamoon Noushad role: CONTACT phone: 03333549258 lat: 24.8608 lon: 67.0104 hasResults: False
nctId: NCT06316440 id: noise and postoperative pain briefTitle: Effect of Noise Isolation on the Incidence of Moderate to Severe Postoperative Pain overallStatus: RECRUITING date: 2024-03-12 date: 2024-12 date: 2024-12 date: 2024-03-18 date: 2024-03-28 name: The Second Affiliated Hospital of Chongqing Medical University class: OTHER name: The First Affiliated Hospital of Zhengzhou University name: Shapingba People's Hospital of Chongqing University name: Chongganng General Hospital name: Wuhan University name: Tongji Hospital briefSummary: To investigate the effect of noise isolation during general anesthesia on the incidence of moderate to severe postoperative pain in patients undergoing major abdominal surgery. The aim of this study was to determine whether noise isolation can reduce the Incidence of moderate to severe postoperative pain and analgesic use. conditions: Postoperative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients were randomly divided into intervention group（noise blocking） and control group（No noise blocking） primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 304 type: ESTIMATED name: Wear noise-cancelling earphones measure: The incidence of moderate to severe postoperative pain measure: Patient controlled analgesia pump analgesic consumption measure: Patient controlled analgesia pump analgesic consumption measure: The incidence of additional analgesic requirements measure: Maximum pain score (NRS score) at 0-48 hours postoperatively measure: The incidence of moderate to severe postoperative pain measure: Accumulative postoperative pain NRS measure: Pain score (NRS score) at 0-6 hours postoperatively measure: Pain score (NRS score) at 6-12 hours postoperatively measure: Pain score (NRS score) at 12-24 hours postoperatively measure: Pain score (NRS score) at 24-48 hours postoperatively sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Anesthesiology, The Second Affiliated Hospital, Chongqing Medical University status: RECRUITING city: Chongqing state: Chongqing zip: 400010 country: China name: Guangyou Duan, MD role: CONTACT phone: (+86)18323376014 email: duangy@hospital.cqmu.edu.cn lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06316427 id: BJGBYY-IIT-LCYJ-2024-003 briefTitle: Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma overallStatus: RECRUITING date: 2024-03-22 date: 2026-04-01 date: 2028-03-30 date: 2024-03-18 date: 2024-03-25 name: Beijing GoBroad Hospital class: OTHER briefSummary: This is a single-center, open-label, non-randomized, phase I/II trial. Patients with refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) will receive autologous, prior-HSCT donor-derived or new donor-derived CD7 CAR T cells according to their HSCT history, peripheral blood leukemia burden and at their discretion. The primary objective is to learn about the safety of autologous, prior-HSCT donor-derived and new donor-derived CD7 CAR T-cell therapy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia and lymphoma (r/r T-ALL/T-LBL) in phase I and to learn about the efficacy of autologous, prior-HSCT donor-derived and new donor-derived CD7 CAR T-cell therapy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia and lymphoma (r/r T-ALL/T-LBL) in phase II. The primary endpoint is type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR T-cell infusion in phase I and overall response rate (ORR), which includes CR, CRh, CRi, MLFS, aplastic marrow for blood and bone marrow; central nervous system (CNS) remission; CR and PR for lymphomatous extramedullary disease according to National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia at 3 months (± 1 week) post CD7 CAR T-cell infusion in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells in phase II. A total number of 80 subjects will be enrolled. conditions: T-cell Acute Lymphoblastic Leukemia conditions: Acute Lymphoblastic Leukemia, in Relapse conditions: Refractory Acute Lymphoblastic Leukemia studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Investigator Initiate Trial primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Autologous CD7 CAR T-cell name: Prior-HSCT donor-derived CD7 CAR T-cell name: New donor-derived CD7 CAR T-cell measure: Dose-Limiting Toxicity (DLT) in phase I measure: Overall Response Rate (ORR) in phase II measure: Overall Response Rate (ORR) in phase I measure: Safety in phase II measure: Progression-Free Survival (PFS) in phase II measure: Duration of Remission (DOR) in phase II measure: Overall Survival (OS) in phase II measure: Levels of CD7 CAR-T Cells in phase II measure: Levels of CAR transgene in phase II measure: Levels of immune cells in phase II measure: Levels of cytokines in phase II sex: ALL minimumAge: 1 Year maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing GoBroad Hospital status: RECRUITING city: Beijing state: Beijing zip: 102206 country: China lat: 39.9075 lon: 116.39723 hasResults: False